Wu Yutong, Wu Hao, Yi Hang
Clinical Medicine, Chongqing Medical University, University of Leicester Joint Institute, Chongqing, China.
Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.
Front Pharmacol. 2025 May 27;16:1610426. doi: 10.3389/fphar.2025.1610426. eCollection 2025.
Metabolic associated fatty liver disease (MAFLD) is a common liver disease worldwide. However, effective therapies are still lacking. This meta-analysis aimed to compare the efficacy of interventions with or without live combined and (LCBE) enteric-coated capsules in MAFLD patients, thereby providing some reference for clinicians in optimizing treatment strategies.
Embase, PubMed, Web of Science, Cochrane Library, Wan Fang, China Science and Technology Journal Database, China National Knowledge Infrastructure, and China Biomedical Literature Service System were searched for relevant randomized controlled trials (RCTs). MAFLD patients receiving interventions with or without LCBE enteric-coated capsules were categorized into the experimental or control group, respectively.
This meta-analysis included 21 RCTs with 1783 MAFLD patients. The effective rate was higher in the experimental group than in the control group ( < 0.001). The normal and light fatty liver rate was increased in the experimental group compared to the control group ( = 0.003). Aspartate transaminase, alanine aminotransferase, and gamma-glutamyl transferase were lower in the experimental group than the control group (all < 0.01). Body mass index, fasting blood glucose, triglyceride, total cholesterol, and low-density lipoprotein cholesterol were lower, and high-density lipoprotein cholesterol was higher in the experimental group than the control group (all < 0.05). C-reactive protein, interleukin-6, tumor necrosis factor-alpha, and endotoxin were lower in the experimental group than in the control group (all < 0.01).
Interventions containing LCBE enteric-coated capsules exhibit satisfactory efficacy, which improve liver function, metabolic status, and inflammation compared to those without LCBE enteric-coated capsules in MAFLD patients.
代谢相关脂肪性肝病(MAFLD)是全球常见的肝脏疾病。然而,仍缺乏有效的治疗方法。本荟萃分析旨在比较MAFLD患者接受含或不含活组合和(LCBE)肠溶胶囊干预的疗效,从而为临床医生优化治疗策略提供一些参考。
检索Embase、PubMed、Web of Science、Cochrane图书馆、万方、中国科技期刊数据库、中国知网和中国生物医学文献服务系统,查找相关随机对照试验(RCT)。接受含或不含LCBE肠溶胶囊干预的MAFLD患者分别分为试验组或对照组。
本荟萃分析纳入了21项RCT,共1783例MAFLD患者。试验组的有效率高于对照组(<0.001)。与对照组相比,试验组的正常和轻度脂肪肝发生率增加(=0.003)。试验组的天冬氨酸转氨酶、丙氨酸转氨酶和γ-谷氨酰转移酶低于对照组(均<0.01)。试验组的体重指数、空腹血糖、甘油三酯、总胆固醇和低密度脂蛋白胆固醇较低,高密度脂蛋白胆固醇较高(均<0.05)。试验组的C反应蛋白、白细胞介素-6、肿瘤坏死因子-α和内毒素低于对照组(均<0.01)。
与不含LCBE肠溶胶囊的干预措施相比,含LCBE肠溶胶囊的干预措施在MAFLD患者中表现出令人满意的疗效,可改善肝功能、代谢状态和炎症。